| Drug Name: | Ofloxacin (82419-36-1) |
|---|---|
| PubChem ID: | 4583 |
| SMILES: | CC1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O |
| InchiKey: | GSDSWSVVBLHKDQ-UHFFFAOYSA-N |
| Therapeutic Category: | Anti-Bacterial Agents, Anti-Infective Agents, Antineoplastic Agents, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme Inhibitors, Enzyme Inhibitors, Nucleic Acid Synthesis Inhibitors, Renal Agents, Topoisomerase II Inhibitors, Topoisomerase Inhibitors |
| Molecular Weight (dalton) | : | 361.373 |
| LogP | : | 1.544 |
| Ring Count | : | 2 |
| Hydrogen Bond Acceptor Count | : | 6 |
| Hydrogen Bond Donor Count | : | 1 |
| Total Polar Surface Area | : | 75.01 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|---|---|---|---|
| Fenbufen (36330-85-5) | Convulsions | Antagonistic | Not fully understood Experiments in mice have shown that quinolones competitively inhibit the binding of gamma-amino butyric acid (GABA) to its receptors the NSAID simply lowers the amount of quinolone needed to precipitate convulsions in already susceptible individuals | Effects of ketoprofen (NSAID) on the pharmacokinetics of pefloxacin and ofloxacin in healthy volunteers |
| Warfarin (81-81-2) | Bleeding | Antagonistic | Uncertain. It is not clear what factors might have been responsible in those cases where the effects of the anticoagulants were increased | Ofloxacin and warfarin |
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category